Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Active:	No
Cancer Type:	Leukemia	NCT ID:	NCT03825367
Trial Phases:	Phase I Phase II	Protocol IDs:	T2016-002 (primary) NCI-2019-06317
Eligibility:	1 - 30 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Therapeutic Advances in Childhood Leukemia Consortium
NCI Full Details:	http://clinicaltrials.gov/show/NCT03825367

Summary

This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric
patients with relapsed/refractory acute myeloid leukemia

Objectives

This proposed study will be the first to test nivolumab in combination with AZA in pediatric
patients with hematologic malignancies. Patients will receive the first dose of nivolumab on
day 1 along with AZA. After "chemotherapy priming", a second dose of nivolumab will be given
at day 15 which will enhance the effect of nivolumab on the regenerating CD4+ and CD8+ memory
T cells.

To establish a recommended Phase II dose (RP2D)of nivolumab in combination with 5-azacytidine
in children with relapsed or refractory AML. To assess the clinical activity of Nivolumab in
combination with 5-azacytidine in AML patients with M2/M3 disease at study entry.

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.